Conditions: creatinine · two weeks · survodutide.
This is not behaving the way I expected and I want to understand the discrepancy before I act on it.
I have photographed the current state and recorded the conditions, so I can answer follow-up questions precisely.
How do I distinguish the benign explanation from the one that matters?
2 weeks is 14 days, and the first question about any marker is whether 14 days is long enough for it to have finished moving. Creatinine is produced from muscle at a rate proportional to how much of it there is, so a falling creatinine during weight loss is a body-composition result before it is a renal one. Against 14 days the marker is at or near the edge of its own settling time, so part of what you are reading is the transition rather than the destination. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 14 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Research-use compounds are not approved for human use, and no panel makes that safer.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
The part that matters: a sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Keep the full report, not the number. You will need the units and the interval later.
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
The underlying point is that a twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Decide the action for each result before you order the test.
edited 14 Oct 2025 by Dr_Rosalind_Achebe — fixed an arithmetic slip in the third paragraph
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
The caveat is the population. Trial participants were screened, monitored and supported; the effect size in an unmonitored setting is not the trial effect size, and it is not obvious in which direction the difference runs.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 1 Jul 2025 by thabo_maseko — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.